Awards & Advancement

SynteractHCR adds three senior executives to management team

Thursday, April 20, 2017

SynteractHCR, a full-service, international CRO, has appointed three new senior-level managers to its leadership team to ensure internationally-cohesive, enhanced support for sponsors. SynteractHCR’s newest senior executives include: Heather Davis, executive director of U.S. Project Management; Zia Haque, executive director, Clinical Data Management, and John Whitaker, Ph.D. as executive director, Biostatistics. All will report to Marlo M. Vasquez, vice president, U.S. Operations at SynteractHCR.

[Read More]

MJFF promotes Sohini Chowdhury to deputy CEO

Thursday, April 20, 2017

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the promotion of Sohini Chowdhury to the role of deputy chief executive officer. In her previous capacity as senior vice president, Research Partnerships, Chowdhury was instrumental in driving the Foundation’s innovative alliances with key Parkinson’s research stakeholders for the benefit of the estimated five million people worldwide living with Parkinson’s disease.

[Read More]

Axovant Sciences appoints Dr. David Hung CEO, Marion McCourt as president and COO

Tuesday, April 18, 2017

Axovant Sciences, a clinical stage biopharmaceutical company focused on the treatment of dementia, announced that David Hung, M.D., has been named chief executive officer of Axovant Sciences, effective April 7, 2017. Dr. Hung, who also joined Axovant’s board of directors, succeeds founding chief executive officer Vivek Ramaswamy. Ramaswamy will continue to serve on Axovant’s board of directors and will lead parent company and majority owner Roivant Sciences as its full-time chief executive officer.

[Read More]

Ipsen appoints Dr. Alexandre Lebeaut as EVP, R&D, and chief scientific officer

Tuesday, April 18, 2017

Ipsen announced the appointment of Dr. Alexandre Lebeaut as executive vice president, R&D, and chief scientific officer, effective immediately. Dr. Lebeaut will report directly to David Meek, CEO of Ipsen, and serve on the executive leadership team. Dr. Lebeaut joined Ipsen in 2013 as senior vice president, chief development officer, Global Drug Development and was appointed interim head of R&D in December 2016.

[Read More]

ICON awarded Best CRO at World Vaccine Congress 2017

Friday, April 14, 2017

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has been awarded Best Clinical Research Organisation at the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place in Washington this week.

[Read More]